Literature DB >> 18973791

Spinal antinociceptive action of loperamide is mediated by opioid receptors in the formalin test in rats.

Subrata Basu Ray1, Tony L Yaksh.   

Abstract

Opioids like morphine produce antinociception after intrathecal administration. Being hydrophilic in nature, morphine also spreads rostrally which leads to respiratory depression. Loperamide has been reported to produce antinociception after both intracisternal and intrathecal administration. It is also hydrophobic, which could restrict its diffusion in the spinal canal. However, the mechanism of its antinociceptive action after intrathecal administration is not definitely known. In the present study, the antinociceptive effect of loperamide was evaluated by the formalin test. It significantly inhibited Phase II flinching behavior. This antinociceptive effect was reversed by pre-administration of naloxone indicating that it was predominantly due to activation of opioid receptors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18973791      PMCID: PMC2753543          DOI: 10.1016/j.neulet.2008.10.067

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  20 in total

1.  Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity.

Authors:  D L DeHaven-Hudkins; L C Burgos; J A Cassel; J D Daubert; R N DeHaven; E Mansson; H Nagasaka; G Yu; T Yaksh
Journal:  J Pharmacol Exp Ther       Date:  1999-04       Impact factor: 4.030

Review 2.  The formalin test: an evaluation of the method.

Authors:  Arne Tjølsen; Odd-Geir Berge; Steinar Hunskaar; Jan Henrik Rosland; Kjell Hole
Journal:  Pain       Date:  1992-10       Impact factor: 6.961

Review 3.  Preclinical assessment of candidate analgesic drugs: recent advances and future challenges.

Authors:  S S Negus; T W Vanderah; M R Brandt; E J Bilsky; L Becerra; D Borsook
Journal:  J Pharmacol Exp Ther       Date:  2006-06-02       Impact factor: 4.030

4.  A prospective randomized double-blind trial of the use of intrathecal fentanyl in patients undergoing lumbar spinal surgery.

Authors:  Jason H H Chan; Giles N A Heilpern; Iain Packham; Ravi K Trehan; Gavin D J Marsh; Aston A Knibb
Journal:  Spine (Phila Pa 1976)       Date:  2006-10-15       Impact factor: 3.468

5.  Pain relief by intrathecally applied morphine in man.

Authors:  J K Wang; L A Nauss; J E Thomas
Journal:  Anesthesiology       Date:  1979-02       Impact factor: 7.892

6.  Acute analgesic effect of loperamide as compared to morphine after intrathecal administration in rat.

Authors:  Subrata Basu Ray; Dilip Verma; Shashi Wadhwa
Journal:  Indian J Exp Biol       Date:  2005-05       Impact factor: 0.818

Review 7.  Opioids in the brain: supraspinal mechanisms in pain control.

Authors:  T S Jensen
Journal:  Acta Anaesthesiol Scand       Date:  1997-01       Impact factor: 2.105

8.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

Authors:  A H Schinkel; E Wagenaar; C A Mol; L van Deemter
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

9.  Rostral spread of epidural morphine.

Authors:  P R Bromage; E M Camporesi; P A Durant; C H Nielsen
Journal:  Anesthesiology       Date:  1982-06       Impact factor: 7.892

10.  Blocking mu opioid receptors in the spinal cord prevents the analgesic action by subsequent systemic opioids.

Authors:  Shao-Rui Chen; Hui-Lin Pan
Journal:  Brain Res       Date:  2006-02-24       Impact factor: 3.252

View more
  2 in total

1.  Dual effects of brain sparing opioid in newborn rats: Analgesia and hyperalgesia.

Authors:  Gong Kerui; Luc Jasmin
Journal:  Neurobiol Pain       Date:  2018-01-10

2.  Evidence for a role of NTS2 receptors in the modulation of tonic pain sensitivity.

Authors:  Geneviève Roussy; Marc-André Dansereau; Stéphanie Baudisson; Faouzi Ezzoubaa; Karine Belleville; Nicolas Beaudet; Jean Martinez; Elliott Richelson; Philippe Sarret
Journal:  Mol Pain       Date:  2009-07-06       Impact factor: 3.395

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.